Your browser doesn't support javascript.
loading
Germline predisposition traits in allogeneic hematopoietic stem-cell transplantation for myelodysplastic syndromes: a survey-based study and position paper on behalf of the Chronic Malignancies Working Party of the EBMT.
Gurnari, Carmelo; Robin, Marie; Godley, Lucy A; Drozd-Sokolowska, Joanna; Wlodarski, Marcin W; Raj, Kavita; Onida, Francesco; Worel, Nina; Ciceri, Fabio; Carbacioglu, Selim; Kenyon, Michelle; Aljurf, Mahmoud; Bonfim, Carmem; Makishima, Hideki; Niemeyer, Charlotte; Fenaux, Pierre; Zebisch, Armin; Hamad, Nada; Chalandon, Yves; Hellström-Lindberg, Eva; Voso, Maria Teresa; Mecucci, Cristina; Duarte, Fernando Barroso; Sebert, Marie; Sicre de Fontbrune, Flore; Soulier, Jean; Shimamura, Akiko; Lindsley, R Coleman; Maciejewski, Jaroslaw P; Calado, Rodrigo T; Yakoub-Agha, Ibrahim; McLornan, Donal P.
Afiliação
  • Gurnari C; Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy; Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
  • Robin M; Department of Hematology and Bone Marrow Transplantation, Hôpital Saint-Louis, AP-HP, University Paris, Paris, France.
  • Godley LA; Section of Hematology and Oncology, Departments of Medicine and Human Genetics, The University of Chicago, Chicago, IL, USA.
  • Drozd-Sokolowska J; Department of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw, Warsaw, Poland.
  • Wlodarski MW; Department of Hematology, St Jude Children's Research Hospital, Memphis, TN, USA.
  • Raj K; University College London NHS Foundation Trust, London, UK.
  • Onida F; Hematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
  • Worel N; Department of Transfusion Medicine and Cell Therapy, Medical University of Vienna, Vienna, Austria.
  • Ciceri F; IRCCS Ospedale San Raffaele, Milano, Italy.
  • Carbacioglu S; Department of Paediatric Oncology, Haematology and Stem Cell Transplantation, University Children's Hospital Regensburg, Regensburg, Germany.
  • Kenyon M; Department of Haematological Medicine, King's College Hospital NHS Foundation Trust, London, UK.
  • Aljurf M; Division of Hematology, Stem Cell Transplantation and Cellular Therapy, Oncology Center, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
  • Bonfim C; Pediatric Blood and Marrow Transplantation Division and Pele Pequeno Principe Research Institute, Hospital Pequeno Principe, Curitiba, Brazil.
  • Makishima H; Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan.
  • Niemeyer C; Department of Pediatrics and Adolescent Medicine, Division of Pediatric Hematology and Oncology, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Fenaux P; Department of Hematology and Bone Marrow Transplantation, Hôpital Saint-Louis, AP-HP, University Paris, Paris, France; INSERM U944, CNRS UMR7212, Paris, France; Saint-Louis Hospital, Hematology Laboratory, AP-HP, Paris, France.
  • Zebisch A; Division of Hematology and Otto Loewi Research Center for Vascular Biology, Immunology and Inflammation, Division of Pharmacology, Medical University of Graz, Graz, Austria.
  • Hamad N; Department of Hematology, St Vincent's Hospital Sydney, NSW, Australia.
  • Chalandon Y; Division of Hematology, Bone Marrow Transplant Unit, University Hospital of Geneva and Faculty of Medicine, University of Geneva, Geneva, Switzerland.
  • Hellström-Lindberg E; Center for Hematology and Regenerative Medicine, Department of Medicine Huddinge, Karolinska Institutet and Department of Hematology, Karolinska University Hospital, Stockholm, Sweden.
  • Voso MT; Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.
  • Mecucci C; Institute of Hematology and Center for Hemato-Oncology Research, University and Hospital of Perugia, Perugia, Italy.
  • Duarte FB; Federal University of Ceará, Fortaleza, Brazil.
  • Sebert M; Department of Hematology and Bone Marrow Transplantation, Hôpital Saint-Louis, AP-HP, University Paris, Paris, France; INSERM U944, CNRS UMR7212, Paris, France; Saint-Louis Hospital, Hematology Laboratory, AP-HP, Paris, France.
  • Sicre de Fontbrune F; Department of Hematology and Bone Marrow Transplantation, Hôpital Saint Louis, AP-HP, Université Paris Cité, Centre National de Reference des Aplasies Médullaires Acquises et Constitutionnelles, Paris, France.
  • Soulier J; INSERM U944, CNRS UMR7212, Paris, France; Saint-Louis Hospital, Hematology Laboratory, AP-HP, Paris, France.
  • Shimamura A; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA.
  • Lindsley RC; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Maciejewski JP; Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
  • Calado RT; Department of Medical Imaging, Hematology, and Oncology, Ribeirão Preto Medical School, University of São Paulo, Brazil.
  • Yakoub-Agha I; CHU de Lille, University of Lille, INSERM U1286, Lille, France.
  • McLornan DP; University College London NHS Foundation Trust, London, UK. Electronic address: donal.mclornan@nhs.net.
Lancet Haematol ; 10(12): e994-e1005, 2023 Dec.
Article em En | MEDLINE | ID: mdl-37898151
The recent application of whole exome or whole genome sequencing unveiled a plethora of germline variants predisposing to myeloid disorders, particularly myelodysplastic neoplasms. The presence of such variants in patients with myelodysplastic syndromes has important clinical repercussions for haematopoietic stem-cell transplantation, from donor selection and conditioning regimen to graft-versus-host disease prophylaxis and genetic counselling for relatives. No international guidelines exist to harmonise management approaches to this particular clinical scenario. Moreover, the application of germline testing, and how this informs clinical decisions, differs according to the expertise of individual clinical practices and according to different countries, health-care systems, and legislations. Leveraging the global span of the European Society for Blood and Marrow Transplantation (EBMT) network, we took a snapshot of the current European situation on these matters by disseminating an electronic survey to EBMT centres experienced in myelodysplastic syndromes transplantation. An international group of haematologists, transplantation physicians, paediatricians, nurses, and experts in molecular biology and constitutional genetics with experience in myelodysplastic syndromes contributed to this Position Paper. The panel met during multiple online meetings to discuss the results of the EBMT survey and to establish suggested harmonised guidelines for such clinical situations, which are presented here.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Síndromes Mielodisplásicas / Transplante de Células-Tronco Hematopoéticas / Doença Enxerto-Hospedeiro / Neoplasias Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Síndromes Mielodisplásicas / Transplante de Células-Tronco Hematopoéticas / Doença Enxerto-Hospedeiro / Neoplasias Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article